free web stats

VBI Vaccines Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares and Upsized Registered Direct Offering for Aggregate Proceeds of $71.9 Million

By | Press Releases
VBI Vaccines Inc. (Nasdaq: VBIV) (TSX: VBV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that the underwriters of its previously announced underwritten public offering have exercised their option to purchase an additional 2,100,000...
Read More
Subscribe to Receive VBI Email Alerts

Media Contact

Perri Maduri, Communications Executive
Telephone: (617) 830-3031 x124
Email: ir@vbivaccines.com

VBI on Twitter